Pharmaceutical Industry Articles & Reports - Page 3

A 2026 analyst comparison of All of Us, UK Biobank, N3C, MIMIC-IV, SEER, PCORnet, and TriNetX covering access costs, application steps, dataset scale, and AI training suitability.

A 2026 analyst data report on FDA Form 483 and warning letter statistics, covering year-by-year enforcement trends, country-level data, most-cited GMP observations, and documented case studies.

Analysis of CDER's disclosed AI submission counts from 2016 to 2026, the January 2025 AI credibility guidance, the Elsa review tool, and named case studies as of August 2026.

A 2026 data-driven analysis of 340B program statistics: HRSA's $100 billion 2025 purchase total, covered entity growth, 31,593 contract pharmacies, 41 restricting manufacturers, and the HRSA rebate model pilot.

A 2026 analyst data report on clinical trial diversity statistics covering FDA Diversity Action Plan status, enrollment by race, ethnicity, sex and age, and disease-burden gaps in oncology, cardiology, diabetes and Alzheimer's.

A 2026 analyst report on FDA accelerated approval confirmatory trial status: conversion and withdrawal rates, Project Confirm data, FDORA requirements, the 2020-2026 withdrawal list, and 5 case studies.

A 2026 analyst guide to the Medicare Drug Price Negotiation list, covering all 40 selected drugs across three rounds, negotiated Maximum Fair Prices, CMS savings estimates, and pending litigation.

A 2026 analyst guide to CTMS, eTMF, and LIMS pricing comparing Veeva, Medidata, Oracle, LabWare, Thermo Fisher, and LabVantage, with cost ranges, TCO tables, and 9 named case studies.

A 2026 analyst guide to CMS Open Payments data: 2025 program year totals of $14.67 billion, top pharma and medtech payers, payment categories, state breakdowns, and 5 enforcement case studies.

A 2026 analyst guide to FAERS adverse event data covering the FDA's new AEMS platform transition, serious outcome rates, top drugs by report volume, signal detection methods, and AI pharmacovigilance case processing.

A 2026 analyst benchmark report on clinical trial site payments covering per-visit fees, 31 to 35 percent overhead rates, holdback terms, negotiation timelines, and AI payment platforms.

A data-driven 2026 survey of AI-discovered drugs in clinical trials, mapping Insilico Medicine, Recursion Pharmaceuticals, Isomorphic Labs, success rates, funding, and named case studies.

Full 2026 data report on US drug shortages: current FDA and ASHP counts, root causes, sterile injectable and chemotherapy shortages, duration trends, hospital costs, and federal policy response.

A 2026 analyst report ranking the top 25 drugmakers by R&D spending and R&D intensity, with PhRMA, Deloitte, and IQVIA benchmarks, five case studies, and AI's impact on pharma R&D.

A 2026 analyst ranking of top contract research organizations by revenue, covering IQVIA, ICON, Fortrea, Thermo Fisher's PPD, Medpace, and CRO market size, M&A, and book-to-bill trends.

Compares Bristol Myers Squibb, Eli Lilly, and Roche's 2026 AI supercomputers: disclosed GPU counts, Nvidia Vera Rubin vs Blackwell specs, capex and market data, and five named case studies from BMS, Genentech, Recursion, and Insilico Medicine.

A 2026 analyst tracker of FDA novel drug approvals, covering CDER's 29 approvals through July, expedited-pathway data, first-cycle approval rates, and 6 named case studies.

A 2026 analyst report on the cost to bring a drug to market, comparing Tufts CSDD's $2.6 billion figure, Deloitte's $2.671 billion 2025 estimate, and lower academic estimates, with phase-by-phase trial costs and 5 case studies.

A 2026 analyst guide to EDC software pricing comparing Medidata Rave, Veeva Vault EDC, Oracle Clinical One, and Castor, with per-study cost ranges, TCO tables, and 5 case studies.

A 2026 HIPAA compliance analysis of PointClickCare's AI charting tools: the platform BAA, SOC 2 and HITRUST attestations, the $65/month FHIR API, and third-party scribes like RevMaxx, Sully.ai, and Twofold.

A 2026 analyst guide comparing ChatGPT, Claude, and purpose-built AI tools for drafting insurance claim denial appeal letters, covering HIPAA compliance, pricing, denial statistics, and four real-world cases.

A 2026 analyst guide to HIPAA training requirements for medical office staff, covering AI chatbot risks, the 2025 Security Rule proposal, penalty tiers, and enforcement case studies.

A 2026 analyst guide to AI documentation for skilled nursing facilities, covering MDS/PDPM coding assistants, AI scribes, CDI tools, HIPAA compliance, and peer-reviewed evidence on accuracy and ROI.

A July 2026 comparison of Claude Science, GPT-Rosalind, and Isomorphic Labs covering pricing, access models, published benchmarks, named enterprise adoption, and which platform fits which life-sciences use case.